In our TCGA analysis, we observed that the GBM patient groups with high expression of PHGDH, PSAT1, and PSPH display higher expression of EGFR compared to those cases with lower expression of these serine/glycine metabolic enzymes (Fig. 4). The gene discussed is PSAT1; the disease is glioblastoma.